Panamera Holdings Corporation

Panamera Holdings Corporation does not have significant operations. Previously, the company was engaged in the provision of management and consulting services to healthcare organizations. It intends to seek new opportunities or business arrangements primarily in the environmental services industry, emerging innovative technologies, and individual health choices led by innovation and integration. The company was formerly known as Panamera Healthcare Corporation and changed its name to Panamera Holdings Corporation in October 2021. Panamera Holdings Corporation was incorporated in 2014 and is based in Houston, Texas.

Panamera Holdings Corporation trades as PHCI on OTC. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $241,430 of revenue and -$536,414 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Panamera Holdings Corporation can be compared against peers such as Arjo AB (publ), Extendicare Inc., LifeTech Scientific Corporation, Life Healthcare Group Holdings Limited, Life Healthcare Group Holdings Limited, Veradigm Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $192.10M, beta of 4.91, and return on equity of -85.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PHCI currently shows total debt of $80,747 and beta of 4.91. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 8-K (2026-05-12 00:00:00), 4 (2026-04-17 00:00:00), SC 13D/A (2026-04-17 00:00:00), SC 13G (2026-04-13 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.panamerahealth.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.